Korsana Biosciences, Inc. Common Stock
KRSA
15 hedge funds and large institutions have $3.66M invested in Korsana Biosciences, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
3.02% more ownership
Funds ownership: 41.5% → 44.52% (+3%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
11% less capital invested
Capital invested by funds: $4.1M → $3.66M (-$438K)
12% less funds holding
Funds holding: 17 → 15 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$530 |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$97 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$43 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$60.3K |
| 2 |
Jane Street
New York
|
-$55.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$20.9K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.65K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$206 |
KRSA Hedge Fund Activity: Q3 2023 in Review
15 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q3 2023, worth a combined $3.66M — down 11% from $4.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KRSA and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $530. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $60.3K sold.
- 15 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $3.66M of Korsana Biosciences, Inc. Common Stock stock for Q3 2023, down 11% quarter-over-quarter.
- 2 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $530 added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q3 2023 was CAPTRUST Financial Advisors, an estimated $60.3K sold.
Based on aggregated 13F filings for Q3 2023.